APA (7th ed.) Citation

Chan, C., Prozzo, V., Aghevlian, S., & Reilly, R. M. (2022). Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: A theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer. EJNMMI Radiopharmacy & Chemistry, 7(1), 1. https://doi.org/10.1186/s41181-022-00186-9

Chicago Style (17th ed.) Citation

Chan, Conrad, Vanessa Prozzo, Sadaf Aghevlian, and Raymond M. Reilly. "Formulation of a Kit Under Good Manufacturing Practices (GMP) for Preparing [111In]In-BnDTPA-trastuzumab-NLS Injection: A Theranostic Agent for Imaging and Meitner-Auger Electron (MAE) Radioimmunotherapy of HER2-positive Breast Cancer." EJNMMI Radiopharmacy & Chemistry 7, no. 1 (2022): 1. https://doi.org/10.1186/s41181-022-00186-9.

MLA (9th ed.) Citation

Chan, Conrad, et al. "Formulation of a Kit Under Good Manufacturing Practices (GMP) for Preparing [111In]In-BnDTPA-trastuzumab-NLS Injection: A Theranostic Agent for Imaging and Meitner-Auger Electron (MAE) Radioimmunotherapy of HER2-positive Breast Cancer." EJNMMI Radiopharmacy & Chemistry, vol. 7, no. 1, 2022, p. 1, https://doi.org/10.1186/s41181-022-00186-9.